{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:20Z","timestamp":1787016980069,"version":"build-2736575974"},"reference-count":43,"publisher":"BMJ","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2023-076138","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:15:11Z","timestamp":1708496111000},"page":"e076138","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion"],"prefix":"10.1136","volume":"384","author":[{"given":"Neeraj G","family":"Patel","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2025110102261083000_384.feb21_2.e076138.1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31753"},{"key":"2025110102261083000_384.feb21_2.e076138.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7619"},{"key":"2025110102261083000_384.feb21_2.e076138.3","unstructured":"US Food and Drug Administration. Frequently asked questions: breakthrough therapies. 2022. https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/frequently-asked-questions-breakthrough-therapies"},{"key":"2025110102261083000_384.feb21_2.e076138.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMhpr1713338"},{"key":"2025110102261083000_384.feb21_2.e076138.5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5355"},{"key":"2025110102261083000_384.feb21_2.e076138.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16984"},{"key":"2025110102261083000_384.feb21_2.e076138.7","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5311"},{"key":"2025110102261083000_384.feb21_2.e076138.8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50991"},{"key":"2025110102261083000_384.feb21_2.e076138.9","unstructured":"Government Accountability Office. Prescription drugs: Medicare spending on drugs with direct-to-consumer advertising. 2021. https:\/\/www.gao.gov\/products\/gao-21-380"},{"key":"2025110102261083000_384.feb21_2.e076138.10","unstructured":"US Food and Drug Administration. The impact of direct-to-consumer advertising. 2015. https:\/\/www.fda.gov\/drugs\/information-consumers-and-patients-drugs\/impact-direct-consumer-advertising"},{"key":"2025110102261083000_384.feb21_2.e076138.11","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4274-9"},{"key":"2025110102261083000_384.feb21_2.e076138.12","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2220"},{"key":"2025110102261083000_384.feb21_2.e076138.13","doi-asserted-by":"publisher","DOI":"10.1370\/afm.611"},{"key":"2025110102261083000_384.feb21_2.e076138.14","unstructured":"Virginia State Board of Pharmacy v Virginia Citizens Consumer Council (1976), No 74-895. https:\/\/www.law.cornell.edu\/supremecourt\/text\/425\/748"},{"key":"2025110102261083000_384.feb21_2.e076138.15","first-page":"669","article-title":"Direct-to-consumer pharmaceutical advertising: therapeutic or toxic?","volume":"36","author":"Ventola","year":"2011","journal-title":"P T"},{"key":"2025110102261083000_384.feb21_2.e076138.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19320"},{"key":"2025110102261083000_384.feb21_2.e076138.17","unstructured":"Radar M. DTC pharma ad trends: overview and new advertisers. Media Radar, 10 May 2022. https:\/\/mediaradar.com\/blog\/dtc-pharma-ad-trends-overview-new-advertisers\/"},{"key":"2025110102261083000_384.feb21_2.e076138.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06218-x"},{"key":"2025110102261083000_384.feb21_2.e076138.19","doi-asserted-by":"crossref","unstructured":"Alpert A, Lakdawalla D, Sood N. Prescription drug advertising and drug utilization: the role of Medicare Part D. National Bureau of Economic Research, 2015. https:\/\/www.nber.org\/papers\/w21714","DOI":"10.3386\/w21714"},{"key":"2025110102261083000_384.feb21_2.e076138.20","doi-asserted-by":"publisher","DOI":"10.1086\/374704"},{"key":"2025110102261083000_384.feb21_2.e076138.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.12.015"},{"key":"2025110102261083000_384.feb21_2.e076138.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.21041"},{"key":"2025110102261083000_384.feb21_2.e076138.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.16.1995"},{"key":"2025110102261083000_384.feb21_2.e076138.24","doi-asserted-by":"publisher","DOI":"10.1257\/pol.2.4.1"},{"key":"2025110102261083000_384.feb21_2.e076138.25","first-page":"13","article-title":"Direct-to-consumer advertising and pharmaceutical ethics: the case of Vioxx","volume":"35","author":"Green","year":"2006","journal-title":"Hofstra Law Rev"},{"key":"2025110102261083000_384.feb21_2.e076138.26","first-page":"301","article-title":"A new prescription for the opioid epidemic: 360-degree accountability for pharmaceutical companies and their executives","volume":"73","author":"Delfino","year":"2022","journal-title":"Hastings Law J"},{"key":"2025110102261083000_384.feb21_2.e076138.27","doi-asserted-by":"publisher","DOI":"10.1080\/10410236.2019.1584781"},{"key":"2025110102261083000_384.feb21_2.e076138.28","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.17.1.6"},{"key":"2025110102261083000_384.feb21_2.e076138.29","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab021"},{"key":"2025110102261083000_384.feb21_2.e076138.30","doi-asserted-by":"publisher","DOI":"10.1017\/jme.2023.27"},{"key":"2025110102261083000_384.feb21_2.e076138.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3434"},{"key":"2025110102261083000_384.feb21_2.e076138.32","unstructured":"FDA. Breakthrough therapy approvals. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/breakthrough-therapy-approvals"},{"key":"2025110102261083000_384.feb21_2.e076138.33","unstructured":"AdPharm . https:\/\/adpharm.net\/"},{"key":"2025110102261083000_384.feb21_2.e076138.34","unstructured":"Prescrire International. Prescrire\u2019s ratings for new drugs and new indications. https:\/\/english.prescrire.org\/en\/115\/3098\/64002\/8160\/8060\/SubReportDetails.aspx"},{"key":"2025110102261083000_384.feb21_2.e076138.35","unstructured":"Pfizer. Pfizer announces overall survival results from phase 3 Paloma-2 Trial of Ibrance\u00ae (palbociclib) for the first-line treatment of ER+, HER2- metastatic breast cancer. Press release, Jun 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-overall-survival-results-phase-3-paloma-2"},{"key":"2025110102261083000_384.feb21_2.e076138.36","unstructured":"US Food and Drug Administration. Presenting quantitative efficacy and risk information in direct-to-consumer (DTC) promotional labeling and advertisements guidance for industry. FDA, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/presenting-quantitative-efficacy-and-risk-information-direct-consumer-dtc-promotional-labeling"},{"key":"2025110102261083000_384.feb21_2.e076138.37","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4664"},{"key":"2025110102261083000_384.feb21_2.e076138.38","unstructured":"Prescription Drug Advertising. Questions and answers. https:\/\/www.fda.gov\/drugs\/prescription-drug-advertising\/prescription-drug-advertising-questions-and-answers#"},{"key":"2025110102261083000_384.feb21_2.e076138.39","unstructured":"FDA. Code of Federal Regulations Title 2121. 7(ii). 21CFR.202.1. 2022. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=202.1"},{"key":"2025110102261083000_384.feb21_2.e076138.40","doi-asserted-by":"publisher","DOI":"10.1111\/joca.12189"},{"key":"2025110102261083000_384.feb21_2.e076138.41","unstructured":"American Medical Association. AMA calls for ban on DTC ads of prescription drugs and medical devices. 2015. https:\/\/www.ama-assn.org\/press-center\/press-releases\/ama-calls-ban-dtc-ads-prescription-drugs-and-medical-devices"},{"key":"2025110102261083000_384.feb21_2.e076138.42","unstructured":"US Congress. HR 8289\u2014117th congress (2021-2022): Banning Misleading Drug Ads Act 2022. 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/8289\/text"},{"key":"2025110102261083000_384.feb21_2.e076138.43","unstructured":"US Congress. HR 6392\u2014117th Congress (2021-2022): No Tax Breaks for Drug Ads Act. 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/6392"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2023-076138","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2023-076138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:26:19Z","timestamp":1761989179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2023-076138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":43,"alternative-id":["10.1136\/bmj-2023-076138"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2023-076138","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}